Study Design, Baseline and Open-Label Results from XTEND-CIU: A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab through 48 Weeks in Patients with Chronic Idiopathic Urticaria

Study Design, Baseline and Open-Label Results from XTEND-CIU: A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab through 48 Weeks in Patients with Chronic Idiopathic Urticaria

Conclusions A higher-than-expected number of patients responded to omalizumab during the 24-week open-label period and were eligible for randomization in the subsequent double-blind period.

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology Vol. 139; no. 2; p. AB271
Main Authors: Casale, Thomas B., MD, FAAAAI, Scarupa, Mark D., MD, Holden, Michael, MD, MS, Trzaskoma, Benjamin L., MS, Antonova, Evgeniya, MS, PhD, Win, Patrick H., MD
Format: Journal Article
Language:English
Published: St. Louis Elsevier Inc 01-02-2017
Elsevier Limited
Subjects:
Allergy and Immunology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Conclusions A higher-than-expected number of patients responded to omalizumab during the 24-week open-label period and were eligible for randomization in the subsequent double-blind period.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2016.12.874